High Priority
GOG-137A, E-G137
NCI HIGH PRIORITY CLINICAL TRIAL Phase
III Study of Estrogen Replacement Therapy vs Placebo in Women With Stage I or
II Endometrial Adenocarcinoma
Chairperson: Richard R. Barakat. Telephone:
212-639-2453. Lead organization: Gynecologic Oncology Group. Age range: not
specified.
GOG-164, E-G0164
NCI HIGH PRIORITY CLINICAL TRIAL Phase
III Randomized Study of Salvage Therapy With Paclitaxel/Carboplatin vs Stem
Cell Supported High-DoseCarboplatin/Mitoxantrone/Cyclophosphamide
in Persistent Low-Volume Ovarian Epithelial Cancer
Chairperson: William McGuire, III.
Telephone: 404-321-0111. Lead organization: Gynecologic Oncology Group. Age
range: under 66.
Phase III Cervical Cancer
MDA-ID-92027, NCI-P97-0092
Phase III Randomized, Double Blinded, Placebo Controlled Study of Fenretinide
in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3
Chairperson: Michele Follen Mitchell.
Telephone: 713-745-2564. Lead organization: University of Texas - MD Anderson
Cancer Center. Age range: 18 and over.
DUT-KWF-CKVO-9407,
EU-95013 Phase III Randomized Study of
CBDCA/5-FU With Pelvic Radiotherapy vs Radiotherapy Alone for Locally Advanced
Cervical Cancer
Chairperson: E. Pras. Telephone: +31-50-3613674
(Netherlands). Lead organization: Academisch Ziekenhuis Groningen. Age range:
75 and under.
GOG-141
Phase III Study in the Treatment of Bulky Stage IB Carcinoma of the Cervix:
Neoadjuvant CDDP/VCR vs No Neoadjuvant Therapy Followed by Radical Hysterectomy
and Pelvic/Para-aortic Node Dissection
Chairperson: Gary Lee Eddy. Telephone:
715-389-3101. Lead organization: Gynecologic Oncology Group. Age range: no age
specified.
EORTC-55954, COSA,
EU-98061, NSGO-CC-9502, MRC-CE04 Phase
III Study of Radiotherapy With or Without Chemotherapy as Adjuvant Treatment
for Patients With Node Positive Stage IB or IIA Cervical Cancer
Chairperson: Jan Baptist Vermorken.
Telephone: +32-3-821-3954 (Belgium). Lead organization: EORTC Gynecological
Cancer Cooperative Group. Age range: 18 and over.
GOG-169
Phase III Randomized Study of Cisplatin (CDDP) vs Cisplatin Plus Paclitaxel
(Taxol) in Recurrent, Refractory, or Stage IVB Squamous Cell Carcinoma of the
Cervix
Chairperson: David Harry Moore. Telephone:
317-274-2422. Lead organization: Gynecologic Oncology Group. Age range: not
specified.
GOG-165 Phase
III Randomized Comparison Study of Radiotherapy Plus Cisplatin vs Radiotherapy
Plus Fluorouracil in Patients With Uterine Cervix Carcinoma
Chairperson: Rachelle M. Lanciano.
Telephone: 610-284-8240. Lead organization: Gynecologic Oncology Group. Age
range: any age.
Phase III Ovarian
Epithelial Cancer
MRC-OV06, EU-98063
Phase III Randomized Study of Chemotherapy With or Without Interval Debulking
Surgery in Patients With Stage II or III Ovarian Epithelial Cancer Suboptimally
Debulked at Primary Surgery
Chairperson: Julia Bland. Telephone:
+44-0-1223-311110 (United Kingdom). Lead organization: United Kingdom Medical
Research Council. Age range: not specified.
GOG-175
Phase III Randomized Study of Carboplatin and Paclitaxel With or Without Low-Dose
Paclitaxel in Patients With Early-Stage Ovarian Carcinoma
Chairperson: Robert C. Park. Telephone:
215-854-0770. Lead organization: Gynecologic Oncology Group. Age range: not
specified.
MRC-ICON4, EU-96051
Phase III Randomized Study of Paclitaxel With Either Carboplatin or Cisplatin
vs Conventional Platinum-Based Chemotherapy in Relapsed Ovarian Cancer
Chairperson: J. A. Ledermann. Telephone:
+44-171-504-9430 (United Kingdom). Lead organization: United Kingdom Medical
Research Council. Age range: no age specified.
MRC-ICON1, EU-91002
Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen
(eg, CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully
Resected Early-Stage Ovarian Cancer
Chairperson: Christopher J. Williams.
Telephone: +44-186-522-6628 (United Kingdom). Lead organization: United Kingdom
Medical Research Council. Age range: any age.
SEQUUS-30-49, NCI-V97-1257
Phase III Randomized, Open-Label, Comparative Study of Liposomal Doxorubicin
(DOXIL) vs Topotecan HCl in Patients With Epithelial Ovarian Carcinoma Following
Failure of First-Line, Platinum-Based Chemotherapy
Chairperson: Kenneth Cunningham. Telephone:
650-617-3062. Lead organization: SEQUUS Pharmaceuticals, Inc. Age range: 18
and over.
MRC-OV05, EU-96050,
EORTC-55955 Phase III Randomized Study
of the Benefit of Early Chemotherapy Based on CA 125 Level Alone vs Delayed
Chemotherapy Based on Conventional Clinical Indicators for Relapsed Ovarian
Cancer
Chairperson: David Guthrie. Telephone:
+01332-347141, ext 4574 (United Kingdom). Lead organization: United Kingdom
Medical Research Council. Age range: no age specified.
EORTC-55971
Phase III Randomized Study of Neoadjuvant Chemotherapy Followed by Interval
Debulking Surgery vs Upfront Cytoreductive Surgery Followed by Chemotherapy
With or Without Interval Debulking Surgery in Patients With Stage IIIC or IV
Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Chairperson: Ignace B. Vergote. Telephone:
+016-344635 (Belgium). Lead organization: EORTC Gynecological Cancer Cooperative
Group. Age range: not specified.
ANTHRA-A9503
Phase III Randomized Study of Intraperitoneal AD 32 vs Oral Altretamine in Patients
With Refractory or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal
Carcinoma Who Have Failed Platinum and Paclitaxel Chemotherapy
Chairperson: Maurie Markman. Telephone:
216-445-6888. Lead organization: Anthra Pharmaceuticals, Inc. Age range: 18
and over.
EORTC-55904
Phase III Randomized Comparison of Adjuvant Platinum-Containing Chemotherapy
(CDDP or CBDCA With or Without Other Agents) vs No Adjuvant Therapy in Patients
With Stage I/II Ovarian Epithelial Carcinoma
Chairperson: J. Baptist Trimbos. Telephone:
+31-71-526 2845 (Belgium). Lead organization: EORTC Gynecological Cancer Cooperative
Group. Age range: any age.
SWOG-9701
Phase III Randomized Trial of 12 Months vs 3 Months of Paclitaxel in Patients
With Advanced Ovarian Cancer in Complete Remission Following Platinum/Paclitaxel
Based-Chemotherapy
Chairperson: Maurie Markman. Telephone:
216-445-6888. Lead organization: Southwest Oncology Group. Age range: over 65
at registration.
GOG-162
Phase III Randomized Study of 24- vs 96-Hour Infusion of TAX With CDDP for Suboptimal
Stage III/IV Ovarian Epithelial Cancer
Chairperson: David R. Spriggs. Telephone:
212-639-2203. Lead organization: Gynecologic Oncology Group. Age range: 18 and
over.
GOG-152
Phase III Randomized Study of Paclitaxel (Taxol) and Cisplatin (CDDP) Alone
vs Taxol/CDDP With Interval Secondary Cytoreductive Surgery for Suboptimally
Resected Stage III Ovarian Epithelial Carcinoma
Chairperson: Peter Graham Rose. Telephone:
216-844-5011. Lead organization: Gynecologic Oncology Group. Age range: any
age.
GOG-172
Phase III Randomized Study of Intravenous (IV) Paclitaxel and Cisplatin vs IV
Paclitaxel, Intraperitoneal (IP) Cisplatin, and IP Paclitaxel in Patients With
Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma
Chairperson: Deborah K. Armstrong.
Telephone: 410-614-2743. Lead organization: Gynecologic Oncology Group Age range:
not specified.
SWOG-8790, INT-0083,
GOG-133 Phase III Randomized Comparison
of Adjuvant Intraperitoneal Interferon alpha vs No Further Treatment in Patients
With Stage III Ovarian Carcinoma With No Evidence of Disease at Second-Look
Laparotomy Following Platinum-Based Chemotherapy
Chairperson: Edward V. Hannigan. Telephone:
409-772-2368. Lead organization: Southwest Oncology Group. Age range: 18 and
over.
Legend for Abbreviations:
ANTHRA = Anthra Pharmaceuticals,
Inc.
COSA = Clinical Oncology Society
of Australia
DUT-KWF = Koningin Wilhelmina
Fonds (Holland)
E = Eastern Cooperative Oncology
Group
EORTC = European Organization
for Research on Treatment of Cancer
EU = European Voluntary Protocol
GOG = Gynecologic Oncology Group
MDA = MD Anderson Cancer Center
MRC = UK Medical Research Council
NCI = National Cancer Institute
SEQUUS = SEQUUS Pharmaceuticals,
Inc.
SWOG = Southwest Oncology Group